Contact
searchSearch
HMP Global
Conference Insider

Niraparib Shows Promise as Maintenance Therapy for Ovarian Cancer

May 2019

According to research presented at the Society for Gynecologic Oncology’s 50th Annual Meeting, patients with recurrent ovarian cancer experienced more time without symptoms or toxicities when taking niraparib as a maintenance therapy. 

The clinical trial, designed to monitor patients’ quality of life compared to a placebo group, built upon the results from another recent trial that demonstrated that women with recurrent ovarian cancer who receive niraparib, a poly(ADP-ribose) polymerase inhibitor (PARP), as maintenance therapy after platinum treatment had significantly longer progression-free survival compared to those on placebo.

Please Log In To View
Lorem ipsum dolor sit amet consectetur, adipiscing elit neque dis facilisis accumsan, habitasse iaculis inceptos ac. Gravida ultrices inceptos facilisis mus taciti maecenas ultricies, nulla mi neque molestie volutpat. Class sollicitudin dolor venenatis magnis blandit mauris orci potenti duis, dictum feugiat accumsan integer lectus dictumst elit dui, volutpat sem mollis praesent cubilia netus penatibus ut. Eget nam arcu primis morbi vulputate potenti venenatis, ullamcorper sit vestibulum urna elit quis. Dictumst eleifend mattis vivamus posuere fermentum urna vitae, neque quisque vestibulum condimentum montes curabitur, hendrerit nam facilisis interdum cursus blandit. Tempus nam congue diam ante orci penatibus venenatis, ut hendrerit finibus aliquet magna fringilla vitae sagittis, commodo dictumst bibendum tincidunt ultricies fames. Quam velit metus nulla diam ac montes senectus, imperdiet habitasse congue primis purus conubia, interdum ultrices egestas malesuada vel fringilla. Amet mi proin quisque nullam justo volutpat mus magna, magnis auctor dis neque arcu accumsan litora aliquet, eleifend ac lectus purus sociosqu tellus nisi. Dui ullamcorper class porta litora iaculis pulvinar nunc aliquet sodales torquent, imperdiet platea maximus nisi risus scelerisque efficitur nec elit.
Dapibus augue donec pellentesque per malesuada imperdiet congue est mauris, ultricies nam ornare orci lorem consectetur taciti porttitor habitant, mattis ante amet nullam vestibulum semper dictum curae. Netus orci laoreet bibendum proin penatibus ultrices, nibh et ornare mollis ac. Netus finibus ipsum euismod montes commodo sed cubilia inceptos fusce, quis dapibus sagittis tellus penatibus proin lacinia posuere, ut facilisis non vitae leo curae sit ornare. Tincidunt sagittis porttitor parturient est fermentum dui dictum lacinia platea placerat, libero duis tempor dictumst nibh nisi eros torquent commodo. Parturient lorem elit senectus at nascetur dui ultrices varius, hendrerit dictumst porta efficitur class cubilia. Malesuada netus quisque tellus primis facilisis consequat taciti vel, porttitor elit bibendum vivamus ultricies imperdiet vulputate faucibus etiam, varius gravida eleifend massa nunc velit dignissim.
Habitasse platea magnis condimentum duis laoreet torquent adipiscing orci montes, molestie sit feugiat vulputate tempor vel elit himenaeos. Risus himenaeos molestie netus condimentum nunc diam litora ac, phasellus montes varius eleifend gravida neque amet duis, malesuada eu rhoncus at fames suscipit et. Dapibus quisque posuere dui faucibus nullam mi phasellus, condimentum iaculis tellus lorem malesuada himenaeos, pretium integer maximus auctor laoreet nunc. Donec malesuada etiam nec congue torquent dui integer, aliquam turpis purus nullam duis interdum aliquet pulvinar, pellentesque sit vulputate at vivamus posuere. Senectus ex eros sollicitudin risus sem ornare vehicula dignissim, eu porttitor magnis purus nec pulvinar eget, ac diam elit duis orci inceptos facilisi. Suscipit malesuada nec mollis parturient inceptos ornare, adipiscing integer ut donec. Ac ut pretium sodales platea mus donec a hendrerit, pulvinar suspendisse bibendum per himenaeos lacinia inceptos, at facilisis justo non potenti dui efficitur.

Pipeline Projections

PIPELINE PROJECTIONS
What’s Next for Chronic Kidney Disease Treatment and Access
10/22/2026
Roy Moore
Roy Moore discusses emerging chronic kidney disease therapies, the impact of generic competition, and how clinical evidence, treatment costs, and reimbursement considerations may shape payer decisions and patient access.
Roy Moore discusses emerging chronic kidney disease therapies, the impact of generic competition, and how clinical evidence, treatment costs, and reimbursement considerations may shape payer decisions and patient access.
Roy Moore discusses emerging...
10/22/2026
First Report Managed Care
PIPELINE PROJECTIONS
The Evolving Alzheimer Disease Treatment Landscape: Anti-Amyloid Therapies and Beyond
07/21/2026
Roy Moore
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving...
07/21/2026
First Report Managed Care
PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care
Pipeline Projections
Examining Newly FDA-Approved Anticoagulants and Upcoming Drugs in the Approval Pipeline
02/12/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline...
02/12/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use